Navigation Links
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
Date:1/6/2011

ut MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a method for generating cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART™) technology, which allows the company to incorporate multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company has global product development collaborations with Boehringer Ingelheim, Pfizer Inc. and Eli Lilly and Company.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.  

'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
2. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
3. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
4. Paulo F. Costa Joins MacroGenics Board of Directors
5. MacroGenics Appoints New Vice President of Business Development
6. MacroGenics Raises $25M in Series D-2 Financing
7. Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
8. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
9. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
10. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
11. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.Y. , Aug. 21, 2014 ... launch of their Nutraceutical "TELO-20 for Dogs" with ... only Telomere-lengthening supplement in the world for dogs. ... of every chromosome in the body. A wealth ... leading experts in Telomere Science and Aging, including ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary ... by the Jeffrey Epstein VI Foundation , have shown ... identified for elimination. These aggressive cells are the driver mutations ... topological map of what to look for when examining tumors, ... tumor cells can be extracted from biopsy, it,s very difficult ...
(Date:8/21/2014)... , Aug. 21, 2014  Four-dimensional (4-D) ... behaviors based on external stimuli such as changes ... have a disruptive effect in multiple industries.  In ... business landscape by printing objects ranging from human ... automotive sectors. Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
Breaking Biology Technology:Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... to Early Cardiovascular,Events in Asian Populations, WALTHAM, ... ILI ), announced today that Kenneth Kornman, Ph.D., ... findings on,the genetics of cardiovascular disease at the ... place from Oct. 31 -,Nov. 1, 2008, at ...
... Fingerprint portraits go global by incorporating cutting-edge localization technology online to target ... ... New York, NY (PRWEB) October 30, 2008 -- DNA 11, the original ... mark global growth with the launch of a new website that will ...
... databases enable ,researchers to quickly and effectively use these invaluable resources. ... ... announced the availability of newly updated tutorial suites on the DataBase of ... is a public resource for the analysis of promoter regions. , ...
Cached Biology Technology:Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 2Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 3Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 4DNA 11, Creators of DNA Art Goes Global 2Updated Online Tutorials for DBTSS, Pfam and PDB 2Updated Online Tutorials for DBTSS, Pfam and PDB 3
(Date:8/21/2014)... by an international standards process, will be available soon ... invited review published in the OnlineFirst version of ... official journal of the American Society for Parenteral and ... the occurrence of misconnection that can be harmful and ... used to join medical devices, components, and accessories to ...
(Date:8/21/2014)... replicated one of the crucial steps in photosynthesis, opening ... could manufacture hydrogen as a fuel. , "Water is ... prospect to use them to create hydrogen, and do ... the ARC Centre of Excellence for Translational Photosynthesis in ... potential as a zero-carbon replacement for petroleum products, and ...
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2
... in Spanish . , Those who enjoy ... teas may tend to overlook the benefits of drinking herbal ... Research magazine, the idea that herbal teas may provide a ... U.S. Department of Agriculture (USDA)-funded scientists in Boston, Mass., have ...
... March 1, 2011 When patients receive a bone marrow ... cells. Fresh stem cells are needed when a patient is ... blood cells, which can be caused by cancer or even ... that a bone marrow transplant might not succeed because the ...
... has the potential to revolutionise the way autopsies are ... pathologists and radiologists at the University of Leicester in ... The technique developed by a team in the ... Leicester, has been published today (1 March) in ...
Cached Biology News:Don't underestimate the power of herbal teas 2How long do stem cells live? 2New non-surgical autopsy technique set to revolutionize post-mortem practice 2
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning kit ...
... software for the microscopy market by ... components and peripherals with powerful archiving, ... intuitive interface simplifies workflow and speeds ... powerful features such as image stitching, ...
Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
Biology Products: